Santé publique France is France’s national public health agency. A public institution under the authority of the Minister of Health, formed through the merger of several public institutions and established by Order No. 2016-246 of April 15, 2016, the agency works to promote public health. As a scientific, expert, and public health safety agency, its missions include:

1. Epidemiological observation and monitoring of the population’s health status;
2. Monitoring health risks threatening the population;
3. Promoting health and reducing health risks;
4. Developing prevention and health education;
5. Preparation for and response to health threats, alerts, and crises;
6. Issuing public health alerts.

The agency is organized into 12 directorates—some scientific, some cross-functional, and some providing operational support.

The agency’s strategic priorities and work program, established by its Board of Directors, are organized into three areas: Strengthening the capacity for anticipation and rapid response to health threats; Measuring and assessing the extent of diseases and risk factors to guide their prevention and control; Strengthening the health impact of all public policies and the prevention and promotion of health.

Department of Noncommunicable Diseases and Injuries — CaRMeN Unit (Cardiovascular, Respiratory, Metabolic, and Nutrition)

Internship Topic

Chronic Kidney Disease in People with Diabetes in France: A Study of the Determinants of Complication Onset and Healthcare Utilization Based on Data from the ENTRED 3 Cohort. 

CKD in people with diabetes often progresses silently, even though treatments such as glucagon-like peptide-1 agonists (GLP-1 agonists) or sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) can slow its progression.

Research initiated in 2024 estimated the prevalence of CKD in the diabetic population and its underdiagnosis in France based on the ENTRED 3 study (National Representative Control Sample of People with Diabetes, https://santepubliquefrance.fr/Entred3). This is a cross-sectional study that combines data collected via self-administered questionnaires from more than 5,500 people with type 1 or type 2 diabetes in mainland France and the overseas territories, with medical data collected from their physicians and data extracts from the SNDS (National Health Data System) over a 20-year period as part of a passive cohort follow-up (2009–2029).

The cohort study based on SNDS data makes it possible, in particular, to examine the onset of complications and the use of healthcare services among people with diabetes and chronic kidney disease (CKD).

Internship Objectives

Literature review focusing in particular on:

• Diabetes treatments with nephroprotective effects, such as gLP-1 agonists and iSGLT2 inhibitors
• Determinants of the use of these treatments: socioeconomic factors, geographic origin, etc.

Analyses:

• Development of indicators based on reimbursement data for aGLP-1s and iSGLT2 inhibitors from the SNDS
• Descriptive and multivariate statistical analyses

Internship Activities 

• Literature review
• Development of an analysis protocol
• Development of indicators
• Descriptive and multivariate statistical analyses
• Participation in the dissemination of results in the form of an article and a conference presentation